Jiangsu Huiju Pharmaceutical Co., Ltd., founded in 2000 and located in Nantong City, Jiangsu Province, is a pharmaceutical enterprise mainly engaged in high threshold and high value-added characteristic API, and provides new drug cdmo one-stop service for excellent preparation companies at home and abroad. The company has been rated as one of China's top 100 service outsourcing growth enterprises, national intellectual property advantage enterprise, provincial innovative enterprise, provincial major scientific and technological achievement transformation enterprise, provincial innovative team key support enterprise and provincial pilot enterprise of two integration and two industrialization. The company has successively passed the international official certification of the State Food and Drug Administration (nmpa), the Ministry of agriculture of China (MOA), the U.S. Food and Drug Administration (USFDA), the European Union food and Drug Administration (EDQM), the Japan food and Drug Administration (PMDA), the Ministry of food and drug safety of South Korea (MFDs) and so on. The company has a sound process development and quality R & D system, And equipped with dozens of international advanced analysis and testing facilities (currently 251 sets), such as 600Hz NMR, XRPD, Q-TOF, ICPMS, etc. the company has R & D and innovation platforms such as Jiangsu academician workstation, Jiangsu postdoctoral practice base, Jiangsu Engineering Technology Center, Jiangsu enterprise technology center and Jiangsu Engineering Center. It has a high-level, professional and international research and transformation technology team of about 450 people, including Jiang There are 8 innovative talents, 14 doctors and 56 masters in Jiangsu Province. Huiju R & D is in a leading position in the industry in terms of core technology, research and development and innovation level. It has successively undertaken 6 provincial and ministerial projects, including 2 projects of the Ministry of science and technology and 2 special projects for the transformation of major scientific and technological achievements in Jiangsu Province, with a total of 14 million fund support. 46 invention patents were applied for and 13 invention patents were authorized. In recent five years, the company has successfully launched 6 cdmo class I new drug APIs, and 12 cdmo class I new drug APIs are in phase III clinical research. At the same time, the company is committed to the research and development of new pharmaceutical technologies, especially in the fields of asymmetric chiral synthesis, metal selective catalysis, chiral enzyme catalysis and continuous microchannel reaction technology. The company has achieved "high standards, strict requirements and large investment" in the field of safety and environment, strictly abides by the cGMP and other advanced standards of the United States and the European Union, successively passed the iso140001 environmental management system, OHSAS18001 occupational health management system certification, ecovadis certification, and passed the PSCI audit of many international famous pharmaceutical enterprises.